KA-PHARMA: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
KA-PHARMA
Largest movements
- Cash +€56,156
up €56,156 (+255.5%), from €21,976 to €78,133
mainly Net result for the year (+€48,527) and Receivables within one year (+€8,314)
- Receivables within one year -€8,314
down €8,314 (-8.8%), from €94,455 to €86,140
of which Trade receivables: -€9,412
- Profit (loss) carried forward +€48,527
up €48,527 (+45.8%), from €105,946 to €154,474
- Gross operating margin -€55,989
down €55,989 (-52.5%), from €106,679 to €50,690
- Staff costs +€1,239
up €1,239 (+1638.6%), from €76 to €1,315
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €117,458 | €164,964 | +€47,506 | +40.4% |
| Fixed assets | 21/28 | €1,027 | €691 | -€336 | -32.7% |
| Tangible fixed assets | 22/27 | €1,027 | €691 | -€336 | -32.7% |
| Furniture and vehicles | 24 | €1,027 | €691 | -€336 | -32.7% |
| Current assets | 29/58 | €116,431 | €164,273 | +€47,842 | +41.1% |
| Amounts receivable within one year | 40/41 | €94,455 | €86,140 | -€8,314 | -8.8% |
| Trade receivables | 40 | €15,874 | €6,461 | -€9,412 | -59.3% |
| Other amounts receivable | 41 | €78,581 | €79,679 | +€1,098 | +1.4% |
| Cash at bank and in hand | 54/58 | €21,976 | €78,133 | +€56,156 | +255.5% |
| Total equity and liabilities | 10/49 | €117,458 | €164,964 | +€47,506 | +40.4% |
| Equity | 10/15 | €108,946 | €157,474 | +€48,527 | +44.5% |
| Contributions | 10/11 | €3,000 | €3,000 | = | 0.0% |
| Outside capital | 11 | - | €3,000 | +€3,000 | |
| Other | 1109/19 | - | €3,000 | +€3,000 | |
| Profit (loss) carried forward | 14 | €105,946 | €154,474 | +€48,527 | +45.8% |
| Amounts payable | 17/49 | €8,512 | €7,490 | -€1,022 | -12.0% |
| Amounts payable within one year | 42/48 | €8,512 | €7,490 | -€1,022 | -12.0% |
| Trade debts | 44 | €1,635 | €2,156 | +€522 | +31.9% |
| Suppliers | 440/4 | €1,635 | €2,156 | +€522 | +31.9% |
| Taxes, remuneration and social security | 45 | €6,877 | €5,334 | -€1,543 | -22.4% |
| Taxes | 450/3 | €6,877 | €5,334 | -€1,543 | -22.4% |
| Remuneration, social security and pensions | 62 | €76 | €1,315 | +€1,239 | +1638.6% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €336 | €336 | = | 0.0% |
| Other operating charges | 640/8 | €321 | €400 | +€79 | +24.6% |
| Gross operating margin | 9900 | €106,679 | €50,690 | -€55,989 | -52.5% |
| Operating profit (loss) | 9901 | €105,946 | €48,640 | -€57,306 | -54.1% |
| Financial charges | 65/66B | - | €113 | +€113 | |
| Recurring financial charges | 65 | - | €113 | +€113 | |
| Profit (loss) for the period before taxes | 9903 | €105,946 | €48,527 | -€57,419 | -54.2% |
| Profit (loss) for the period | 9904 | €105,946 | €48,527 | -€57,419 | -54.2% |
| Profit (loss) for the period to be appropriated | 9905 | €105,946 | €48,527 | -€57,419 | -54.2% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 6 October 2026 via checked.be.